CN106939320A - A kind of 2012 plants of infective cloned plasmids of Pseudorabies virus JS, construction method and application - Google Patents
A kind of 2012 plants of infective cloned plasmids of Pseudorabies virus JS, construction method and application Download PDFInfo
- Publication number
- CN106939320A CN106939320A CN201710118726.9A CN201710118726A CN106939320A CN 106939320 A CN106939320 A CN 106939320A CN 201710118726 A CN201710118726 A CN 201710118726A CN 106939320 A CN106939320 A CN 106939320A
- Authority
- CN
- China
- Prior art keywords
- pseudorabies virus
- loxp
- plants
- bac
- rjs2012
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16741—Use of virus, viral particle or viral elements as a vector
- C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16761—Methods of inactivation or attenuation
- C12N2710/16762—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention provides a kind of 2012 plants of infective cloned plasmids of Pseudorabies virus JS, construction method and application, based on 2012 plants of the emerging PRV variants JS of China, utilize loxp Cre enzyme systems, in 2012 plants of gG gene end codons downstream insertion pBeloBAC11 carrier sequences of JS, establish 2012 plants of infective cloned plasmids of JS, and genetic sequence operation is carried out to it using galk positive and reverse screenings system, establish the strain reverse genetic operating systems of variant JS 2012, to further investigate the hereditary variation mechanism of PRV variants, virulence strengthens, virus lays dormant infection mechanism and vaccine development etc. provide technology platform.
Description
Technical field
The present invention relates to technical field of bioengineering, more particularly to a kind of Pseudorabies virus infective cloned plasmids and its system
Preparation Method and application.
Background technology
Pseudoabies be by caused by Pseudorabies virus (Pseudorabies virus, PRV) to generate heat, very itch, brain ridge
Marrow inflammation is a kind of important zoonosis of principal character.PRV can infect a variety of hosts, but pig is the main natural place of the virus
Main, storage person and disseminator.The pig of different age group can all infect, and mainly cause in-pig miscarriage, stillborn foetus, mummy tire,
Suckling pig high mortality, and boar infertility.PRV belongs to herpetoviridae A type herpesviral subfamilies, and its genome is wire
Double-stranded DNA, is about 150kb, is made up of long distinct zones (UL), short distinct zones (US) and US both sides repetitive sequence, coding 70
Multiple protein.Some important viral genes, such as gE, gI, gG and tk, exist on virus virulence and significantly affect, its missing can make
Virus weakening.
Pseudo- mad dog betides the U.S. earliest, and China also occurs in that the viral prevalence in early 1960s in swinery,
So far PRV is still widely current in China, seriously threatens the health of China swinery, and causes serious financial consequences.PRV infects
Pig, in addition to high death is presented in suckling pig, other pigs can resistance to mistake.But in the resistance to peripheral nerve cell for crossing pig, there is PRV's
Latent infection.The PRV of latent infection can be activated under certain condition, so that as the infection sources, which increase the difficulty of PRV preventing and treatings
Degree.In order to control PRV, China pig farm widely uses PRV attenuated live vaccines, such as PRV Bartha plants epidemic diseases living since the last century end
Seedling, the pseudorabies incidence of disease is decreased obviously.But since 2011, the immune large-scale pig farm of many use PRV live vaccines goes out
Sow is showed and has produced weak son, stillborn foetus, miscarriage, the clinical symptoms of the pseudo- mad dog such as nervous symptoms and death has occurred in piglet.The country is multiple to grind
Group is studied carefully it has proven convenient that the outburst of China's this time porcine pseudorabies is due to caused by China occurs in that Pseudorabies virus variant.With
Classical PRV strains SC is compared, and Pseudorabies virus variant virulence strengthens, and Bartha vaccines can not be protected completely to variant
Shield.For effective prevention and control PRV variants, it is necessary to which furtheing investigate the hereditary variation of virus and virulence strengthens mechanism.
The content of the invention
The present invention is based on JS-2012 plants of China's emerging PRV variants, using loxp-Cre enzyme systems, in JS-
PBeloBAC11 carrier sequences are inserted in 2012 plants of gG gene end codons downstreams, establish JS-2012 plants of infection clones matter
Grain, and genetic sequence operation is carried out to it using galk positive and reverse screenings system, establish variant JS-2012 strain reverse genetics behaviour
Make system, to further investigate hereditary variation mechanism, virulence enhancing, virus lays dormant infection mechanism and the vaccine development of PRV variants
Deng offer technology platform.
1st, by methods of homologous recombination, in JS-2012 plants of gG gene ORF terminator codons downstream insertions two of Pseudorabies virus
The wing contains loxp EGFP expression cassettes, obtains recombinant virus rJS2012-gG/EGFP；Using Cre enzymes and loxp sites, delete
EGFP expression cassettes, obtain the recombinant virus rJS2012-gG/loxp that loxp is inserted in gG gene ORF terminator codons downstream
2nd, using Cre-loxp, the pBeloBAC11 of EGFP expression cassettes will be inserted between BamHI-HindIII restriction enzyme sites
Carrier is recombined into rJS2012-gG/loxp, is obtained in recombinant virus rJS2012-BAC, the recombinant virus, and pBeloBAC11 is carried
Body sequence is located at gG downstream of gene.
3rd, by the genomic DNA electricity conversion DH10B bacteriums during rJS2012-BAC infection cells, Orbivirus gene
It containing pBeloBAC11, can breed in bacterium, by screening, obtain the plasmid pBAC-JS2012 of viral genomic clone.
PBAC-JS2012 transfectional cells, can produce infectious virus resJS-BAC, show JS-2012 pnca gene group cloned plasmids
PBAC-JS2012 has infectivity.Using Cre enzymes, the pBeloBAC11 sequences in resJS-BAC can be deleted, resJS- is obtained
ΔBAC.ResJS- Δs BAC has and JS-2012 plants of similar growth characteristics of cultured of parental virus and mouse virulence.
4th, by galk screening-genes, gE/gI genes are deleted in pBAC-JS2012 infection clones, and save out
GE/gI gene delections virus resJS- Δs gE/gI.
Invention also provides a kind of Pseudorabies virus infection clones, described Pseudorabies virus infection clones are
It is prepared by the following method what is obtained：
1) by methods of homologous recombination, in Pseudorabies virus gG gene ORF terminator codons downstream, insertion both wings contain
Loxp EGFP expression cassettes, obtain recombinant virus rJS2012-gG/EGFP；Using Cre enzymes and loxp sites, EGFP expression is deleted
Frame, obtains the recombinant virus rJS2012-gG/loxp that loxp is inserted in gG gene ORF terminator codons downstream；
2) Cre-loxp is utilized, the pBeloBAC11 of EGFP expression cassettes will be inserted between BamHI-HindIII restriction enzyme sites
Carrier is recombined into rPRV-gG/loxp, is obtained in recombinant virus rJS2012-BAC, the recombinant virus, pBeloBAC11 carriers
Sequence is located at gG downstream of gene；
3) by the genomic DNA electricity conversion DH10B bacteriums during rJS2012-BAC infection cells, Orbivirus gene
It containing pBeloBAC11, can breed in bacterium, by screening, obtain the plasmid pBAC-JS2012 of viral genomic clone；
It is preferred that, wherein described Pseudorabies virus is selected from JS-2012 plants of PRV variants.
Meanwhile, the present invention also provides a kind of utilization Pseudorabies virus infection clones and is preparing the examination of detection Pseudorabies virus
Purposes in agent or medicine；
Meanwhile, the present invention also provides a kind of Pseudorabies virus infection clones and is preparing prevention or treatment pseudoabies viral disease
Purposes in biological products；
Meanwhile, the present invention also provides a kind of construction method for the Pseudorabies virus infection clones for preparing gE/gI missings, institute
The method of stating comprises the following steps：
1) the plasmid pBAC-JS2012 of viral genomic clone, is obtained；
2), using galk positive and reverse screening systems, gE/gI genes is lacked on PRV infection clones pBAC-JS2012, are obtained
Obtain the Pseudorabies virus infection clones pBACJS- Δs gE/gI of gE/gI missings；
It is preferred that, wherein described Pseudorabies virus is selected from JS-2012 plants of PRV variants；
Meanwhile, the present invention also provides the virus that a variety of utilization Pseudorabies virus infection clones are saved out, including but does not limit
In：resJS-BAC、resJS-ΔBAC、resJS-ΔgE/gI.
Meanwhile, the present invention also provides a kind of Pseudorabies virus infection clones of differentiation gE/gI missings and contaminated with natural sense
The detection method of strain, comprises the following steps：Enter performing PCR using LgEgIF/RgEgIR for primer to identify, it is pseudo- mad that gE/gI is lacked
Dog virus infection clones amplify 1000bp band, are positive bacterium colony, and the natural infection strain of the non-missings of gE/gI is expanded
Bp bands more than 2000.
It should be noted that this method is not just in JS-2012 plants of operation, can apply to many plants of PRV diseases
Strain, those skilled in the art can be by conventional experimental implementation and molecular biology manipulations, in technical solution of the present invention
Under enlightenment, the corresponding operation of other strains is realized.
Brief description of the drawings
Examples of the present invention will be described by way of reference to the accompanying drawings, wherein：
Fig. 1 is, using PRV JS-2012 genomes as template, to be expanded respectively using primer PgGF/PgGR and PDgGF/PDgGR
Left and right sides homology arm, PCR amplification electrophoretograms, wherein, 1：DNA Marker DL2000,2：Left restructuring arm, 3：Right restructuring
Arm；
Fig. 2 is that 2ug pTEGGF are transfected into BHK-21 cell green fluorescence figures using the transfection reagents of FuGENE 6；
Fig. 3 is to use the transfection reagents of FuGENE 6 by 2ug PRV JS-2012 genomes and 1ug pTEGGF plasmid corotation
Contaminate BHK-21 cell green fluorescence figures；
Fig. 4 is recombinant virus rJS2012-gG/loxp PCR amplification qualification result electrophoretograms；
Fig. 5 is recombinant virus rJS2012-gG/loxp PCR amplification qualification result sequence analysis figures；
Fig. 6 is expanded using the primer PEGFPF/PEGFPR PCR for expanding EGFP expression cassettes and identified using pEGFP-C3D as template
As a result electrophoretogram, wherein, 1：DNA Marker DL2000,2：Pcr amplified fragment；
Fig. 7 is that 2ug pBeloBAC11-EGFP are transfected into BHK-21 cell green fluorescences using the transfection reagents of FuGENE 6
Figure；
Fig. 8 is to use the transfection reagents of FuGENE 6 by 1ug pBeloBAC11-EGFP, 1ug pcDNA3.1-cre, 2ug
RJS2012-gG/loxp genome cotransfection BHK-21 cell green fluorescence figures；
Fig. 9 is to carry out restricted enzyme cutting spectrum analysis figure to 3 cloned plasmids using BamHI, wherein, 1：DNA Marker
DL15000；2：Genomic clone plasmid 1；3：Genomic clone plasmid 2；4：Genomic clone plasmid 3；
Figure 10 is to use the transfection reagents of FuGENE 6 by 2 μ g pBAC-JS2012 transfected Vero cells green fluorescence figures；
Figure 11 is PRV JS-2012, resJS-BAC, resJS- Δs BAC viral one step growth curve figure；
Figure 12 is PRV JS-2012, resJS-BAC, resJS- Δs BAC virus plaque lab diagram；
Figure 13 is survival rate after mouse inoculation JS-2012 and resJS- Δ BAC.Wherein, (A) 104TCID50Inoculation；(B)
105TCID50Inoculation；
Figure 14 is, using plasmid pGalk as template, to expand galk expression cassettes PCR using primer galkup/galkdown and expand
As a result electrophoretogram, wherein, 1：DNA Marker DL2000,2：PCR primer；
Figure 15 be using bacterium solution be template, PgBDF/PgBDR and LgalkDF/LgalkDR be primer enter performing PCR screening PCR
Amplification electrophoretogram, wherein, 1：DNA Marker DL2000,2-7：PgBDF/PgBD qualification results, 8-13：LgalkDF/
LgalkDR qualification results；
Figure 16 is, using pBAC-JS2012 as template, to be expanded using primer LgEgIF/LgEgIR and RgEgIF/RgEgIR left
Homology arm PCR amplification electrophoretograms, wherein, 1：DNA Marker DL2000,2：Left homology arm；
Figure 17 is, using pBAC-JS2012 as template, to be expanded using primer LgEgIF/LgEgIR and RgEgIF/RgEgIR right
Homology arm PCR amplification electrophoretograms, wherein, 1：DNA Marker DL2000,2：Right homology arm；
Figure 18 is to screen transfer vector electrophoretogram so that the identification of XhoI and BamHI double digestions is negative, wherein, 1：DNA Marker
DL5000,2：pSKDEI-1、3：pSKDEI-2；
Figure 19 is to enter performing PCR identification electrophoretogram using LgEgIF/RgEgIR for primer, wherein, M1：DNA Marker
DL5000,1-21：Detect sample, c：PJS2012-BAC is compared, M2：DNA Marker DL2000；
Figure 20 is with resBACJS- Δ gE/gI vero cells infection green fluorescence figures；
Figure 21 is to extract resJS- Δ gE/gI genomes, is identified with LgEgIF/RgEgIRPCR, sequencing result figure；
Figure 22 is the expression that the gE albumen in resJS- Δ gE/gI infection cells is detected with IFA, wherein, A：PRV JS-
2012, B：ResJS- Δs gE/gI, C：negative control；
Figure 23 is resJS- Δs gE/gI and parent plant JS-2012 one step growth curve figure；
Figure 24 is resJS- Δs gE/gI and parent plant JS-2012 plaque aspect graph；
Embodiment
In the following example, the experimental method of unreceipted actual conditions, generally routinely condition, such as《Fine works molecular biosciences
Learn experiment guide》(Ma Xuejun, Su Yuelong's translates Beijing by F.M. Ao Sibai, R.E. James Kingstons, the chief editor such as J.G. Sai Deman：Section
Learn publishing house, 2004) described in method carry out.
The present invention, by homologous recombination, is terminated on the basis of Pseudorabies virus variant JS-2012 in viral genome gG
Codon downstream introduces EGFP marker gene and loxp sites, and is deleted using Cre enzymes/loxp recombination system in recombinant virus
EGFP gene, obtain rJS2012-gG/loxp.In the recombination system using Cre enzymes/loxp, the BAC of EGFP gene will be carried
Carrier is recombined into rJS2012-gG/loxp, obtains recombinant virus rJS2012-BAC.During rJS2012-BAC infection cells
Genomic DNA electricity conversion DH10B bacteriums, screening obtain viral genomic clone plasmid pBAC-JS2012.
PBAC-JS2012 transfectional cells, obtain infective viral resJS-BAC, it was demonstrated that pBAC-JS2012 has infection
Property.Viral resJS- Δs BAC using BAC carrier sequence in Cre enzymes/loxp system-kills resJS-BAC has and parent plant
Close JS-2012 growth characteristics and to mouse strong virus force feature.Using galk positive and reverse screening systems, in pBAC-JS2012
The clone pBACJS- Δ gE/gI of gE/gI missings are successfully constructed, gE is not expressed from the viral resJS- Δs gE/gI of Clone Origin
Albumen, it was confirmed that pBAC-JS2012 operability.Infectious gram of the PRV variants JS-2012 that the present invention is successfully constructed
Grand pBAC-JS2012, and its operating method is established, to utilize reverse genetics research virus replication, latent infection and variation
Strain virulence enhancing mechanism, the new attenuated vaccine of exploitation and structure viral vectors etc. are all significant.
Below by embodiment, the present invention is specifically described.
In following embodiments of the present invention, the major experimental material used is as follows：
Virus and cell：(American Cell collection ATCC, preserving number is BHK-21 cells：CCL-10), Vero cells
(American Cell collection ATCC, preserving number is：CCL-81), (this laboratory is preserved Pseudorabies virus variant JS-2012；
Publish an article and see：Separation and the Chinese animals of identification of Pseudorabies virus in sequela piglet is immunized in the such as Tong Wu, Zhang Qingzhan, Zheng Hao
Infectious disease journal, 2013,21 (3)：1-7).
Plasmid and bacterial strain：PBeloBAC11 carriers are ground with Escherichia coli DH10B by Chinese Academy of Agricultural Sciences Harbin animal doctor
Study carefully institute Wang Yunfeng researcher to give, pgalk plasmids are given with Escherichia coli SW102 by He'nan University professor Cao Gengsheng,
PcDNA3.1-cre is purchased from and first biotechnology (Shanghai) limited company, and pEGFP-N1, pEGFP-C3 are purchased from Clontech
Company, pMD18-T, bacillus coli DH 5 alpha are purchased from Takara companies.
Other reagents：Restriction enzyme and T4DNA ligases are purchased from NEB companies, and the transfection reagents of FuGENE 6 are purchased from
Promega companies, hyclone (fetal bovine serum, FBS), MEM, DMEM are purchased from Gibco companies, and plasmid is small to propose examination
Agent box is purchased from extraction reagent kit in QIAGEN companies, plasmid and is purchased from Macherey-Nagel companies, and gel reclaims kit is purchased from wide
State Dongsheng bio tech ltd, PCR reagent is purchased from Takara companies.Reagent needed for positive and reverse screening is purchased from raw work bioengineering
(Shanghai) limited company.
In embodiments of the invention, the cultural method of BHK-21 cells and Vero cells is as follows：
BHK-21 cells in the T25 Tissue Culture Flasks of the MEM culture mediums containing 10%FBS it is adherent cover with individual layer after, abandon
Culture medium in Tissue Culture Flask is removed, and is washed once with PBS, new contain under cell dissociation, will be added with 0.25% pancreatin
10%FBS MEM culture mediums, with 1: 8 ratio point kind in cell bottle or Tissue Culture Plate.
Vero cells in the T25 Tissue Culture Flasks of the DMEM culture mediums containing 10%FBS it is adherent cover with individual layer after, discard
Culture medium in Tissue Culture Flask, and being washed once with PBS, under cell dissociation, will be added with 0.25% pancreatin and new contains 10%
FBS DMEM culture mediums, with 1: 5 ratio point kind in cell bottle or Tissue Culture Plate.
The recombinant virus rJS2012-gG/loxp of embodiment 1 structure
In order to build JS-2012 plants of infection clones of Pseudorabies virus, the present embodiment, will by the method for homologous recombination
In loxp sequences and marker gene EGFP insertion JS-2012 genomes, recombinant virus rJS2012-gG/EGFP is obtained.Pass through again
Cre enzyme effects, delete the EGFP marker gene in rJS2012-gG/EGFP, obtain the recombinant virus rJS2012- for carrying loxp
gG/loxp。
Specific implementation process is as follows：
1.1 transfer vector pTEGGF structure
First by XhoI and BamHI digestion pEGFP-C3, and with T4DNA polymerase filling-in, glue reclaim large fragment
And with T4DNA Ligase connections, obtain and delete XhoI to the plasmid pPEGFP-C3D of multiple cloning sites sequence between BamHI.With
PRV JS-2012 genomes are template, expand left and right respectively using primer PgGF/PgGR (table 1) and PDgGF/PDgGR (table 1)
Side homology arm, PCR amplifications such as Fig. 1 (in Fig. 1,1：DNA Marker DL2000,2：Left restructuring arm, 3：Right restructuring arm), and
Amplified production is connected into pMD18-T, recombinant plasmid pGL-ARM and pGR-ARM is obtained.Utilize SalI and AseI digestions pGL-
ARM, AseI and XbaI enzyme cutting pEGFP-C3D, reclaim small fragment, is connected with T4DNA Ligase into through SalI and XbaI enzyme cutting
PBlueScript SK (+), obtain recombinant plasmid pLARM-EGFP.With AflII and EcoRI difference digestion pGR-ARM and
PEGFP-N1, will connect into pGR-ARM from the pEGFP-N1 polyA fragments cut, obtains recombinant plasmid pRARM-PA.With XhoI
With XbaI enzyme cutting pRARM-PA, small fragment is reclaimed, the pLARM-EGFP through same enzyme digestion is connected into T4DNA Ligase, obtained
Transfer vector pTEGGF.2ug pTEGGF are transfected into BHK-21 cells using the transfection reagents of FuGENE 6,30h after transfection turns
There is green fluorescence expression (Fig. 2) in dye cell.All transfection methods of this explanation enter according to the transfection reagent specifications of FuGENE 6
Row operation.
Pcr amplification primer thing summary sheet in 1 explanation of table
1.2 recombinant virus rJS2012-gG/EGFP
BHK-21 cells are infected with PRV JS-2012,20h after infection, harvesting poison extracts JS- with phenol-chloroform method
2012 genomic DNAs.With the transfection reagents of FuGENE 6 by 2ug PRV JS-2012 genomes and 1ug pTEGGF plasmid co-transfections
BHK-21 cells.36h after transfection, transfectional cell has the cytopathy (Fig. 3) of green fluorescence expression.Treat that 60% cell occurs
Lesion, receives supernatant progress Plaque-purified.The single virus plaque for having green fluorescence by continuous 3 wheel pickings is purified, and is obtained
Respectively there are the recombinant virus of a loxp sites insertion, referred to as rJS2012-gG/EGFP containing EGFP and its both wings.
1.3 recombinant virus rJS2012-gG/loxp
2ug pcDNA3.1-cre are transfected into BHK-21 cells using the transfection reagents of FuGENE 6.10h after transfection, with
0.01MOI recombinant viruses rJS2012-gG/EGFP is infected.70% cytopathy to appear, receives supernatant progress Plaque-purified.
Picking does not have the single virus plaque of green fluorescence, obtains the recombinant virus for not expressing EGFP, referred to as rJS2012-gG/
loxp.And whether delete EGFP using primer gLoxF/gLoxR (table 1) detection recombinant viruses and contain single loxp sites.PCR
Reaction system：94 DEG C of 5min, 94 DEG C of 30s, 68 DEG C of 1min, 68 DEG C of 2min30s, carry out 30 circulations altogether；72℃ 10min.
PCR primer electrophoresis result such as Fig. 4 (1：DNA Marker DL2000,2：Pcr amplified fragment), amplify 1 treaty 550bp bar
Band, it is in the same size with expection.Purpose band is sequenced, sequence is shown in SEQ ID in specification nucleotides and amino acid sequence table
NO.21, sequence analysis (Fig. 5) display, 34bp loxp sequences are successively inserted into PRV gG Orf downstreams.
The recombinant virus rJS2012-BAC of embodiment 2 structure
The present embodiment, by means of the loxp sites in rJS2012-gG/loxp, is marked by loxp-Cre enzyme systems by carrying
Note gene EGFP bacterial artificial chromosome carrier is recombined into rJS2012-gG/loxp, obtains recombinant virus rJS2012-BAC.
Specific implementation process is as follows：
2.1 transfer vector pBeloBAC11-EGFP structure
Using pEGFP-C3D as template, EGFP expression cassettes, PCR reactants are expanded using primer PEGFPF/PEGFPR (table 1)
System：94 DEG C of 5min, 94 DEG C of 30s, 57 DEG C of 45s, 72 DEG C of 2min, carry out 30 circulations altogether；72℃ 10min.PCR primer electricity
Swim result such as Fig. 6 (in Fig. 6,1：DNA Marker DL2000,2：Pcr amplified fragment), amplify 1600bp or so purpose bars
Band., will with T4DNA ligases through glue reclaim with BamHI and HindIII difference digestion target DNA bands and pBeloBAC11
EGFP expression cassettes are connected with pBeloBAC11.Connection product converts DH5 α, with BamHI and HindIII digestion screening positive clones,
Obtain transfer vector pBeloBAC11-EGFP.2ug pBeloBAC11-EGFP are transfected into BHK- using the transfection reagents of FuGENE 6
There is green fluorescence expression (Fig. 7) in 36h after 21 cells, transfection, transfectional cell.
2.2 recombinant virus rJS2012-BAC
According to the method for embodiment 1.2, rJS2012-gG/loxp genomic DNAs are extracted.Will with the transfection reagents of FuGENE 6
1ug pBeloBAC11-EGFP, 1ug pcDNA3.1-cre, 2ug rJS2012-gG/loxp genome cotransfections BHK-21 are thin
Born of the same parents.After cotransfection 36h, it is seen that the expression (Fig. 8) of lesion and green fluorescence.70% cytopathy is treated, supernatant progress plaque is received pure
Change.Picking has the single virus plaque of green fluorescence, carries out the recombinant virus that purifying obtains BAC carrier insertion, name
rJS2012-BAC。
The structure of embodiment 3PRV infectious bacteria artificial chromosomes
The present embodiment by rJS2012-BAC genome electricity by being transformed into Escherichia coli DH10B, and screening, which is obtained, has infection
The plasmid pBAC-JS2012 of property.Specific implementation process is as follows：
Vero cells are infected with rJS2012-BAC, 16-21h after infection extracts rJS2012- in cell using Hirt methods
Ring-type genome in BAC reproduction processes, electricity conversion Escherichia coli DH10B, electric conversion condition is as follows：1mm electricity conversion cups,
1750V, 25 μ F, 200 Ω, electric shock is once.0.8mL S.O.C nutrient solutions are added after electric shock immediately, and electric transformed bacteria is moved into
2.0mL centrifuge tubes, 37 DEG C of culture 1h, 5000rmp centrifugation 2min, are coated on the LB containing chloramphenicol (25 μ g/mL) by precipitation bacterium and put down
Plate, 37 DEG C of culture 24h.Bacterial clump on picking flat board, puts in the LB fluid nutrient mediums containing chloramphenicol (25 μ g/mL), 37
DEG C culture 15h, extract restructuring BAC plasmids.Respectively using PgBDF/PgBDR and PgCDF/gCDR as primer pair, PCR detection restructuring
Whether BAC plasmids, identification contains gB and gC genes.Screening obtains 3 cloned plasmids containing gB, gC gene.Using BamHI to 3
Individual cloned plasmids carry out restricted enzyme cutting spectrum analysis, digestion band electrophoresis result such as Fig. 9 (1：DNA Marker DL15000；
2：Genomic clone plasmid 1；3：Genomic clone plasmid 2；4：Genomic clone plasmid 3), three cloned plasmids BamHI digestions
Collection of illustrative plates is close, more than 15kb bands 2,3 between 7.5kb-10kb, 4 between 5kb-7.5kb, 4,2.5kb between 2.5kb-5kb
1 below.1 band between the difference of one band of presence between cloned plasmids 1 and cloned plasmids 2,3, i.e. 2.5kb-5kb,
Cloned plasmids 1 are bigger than between cloned plasmids 2,3.Bam HI restriction enzyme sites in JS-2012 genome sequences are analyzed, prediction
Big digestion band is consistent with electrophoresis pattern.Cloned plasmids 3 are referred to as pBAC-JS2012 (SEQ ID NO.24), selection is carried out
Follow-up test.
Using the transfection reagents of FuGENE 6 by 2 μ g pBAC-JS2012 transfected Vero cells, 24h after transfection, cell occurs
The cytopathy (Figure 10) of green fluorescence is expressed, treats that cytopathy, up to 70%, harvests supernatant, obtains Revive virus resJS-BAC.
It is above-mentioned test result indicate that, pBAC-JS2012 transfectional cells can produce infectious viral particle, with infectivity.JS-2012 plants
Infection clones pBAC-JS2012 is successfully constructed.
With reference to embodiment 1.3, with the transfection reagents of FuGENE 6 by 2ug pcDNA3.1-cre transfected Vero cells, transfect
10h, is infected with 0.01MOI recombinant viruses resJS-BAC afterwards.70% cytopathy to appear, receives supernatant progress plaque pure
Change.The single plaque for selecting redgreen fluorescent protein expression by three-wheel is purified, and is obtained without BAC carrier sequence
PRV saves strain, referred to as resJS- Δs BAC.With reference to the method for embodiment 1.3, by template of resJS- Δ BAC genomes,
GLoxF/gLoxR is primer, and the sequencing fragment amplified is shown, sequence is consistent with rJS2012-gG/loxp sequence.This table
Bright, BAC carrier sequence can be deleted in Revive virus resJS-BAC, the viral resJS- Δs BAC and recombinant virus of acquisition
RJS2012-gG/loxp has identical hereditary feature.
The Revive virus growth characteristics of embodiment 4 are analyzed
By this embodiment, Revive virus resJS- Δs BAC growth kinetics feature, plaque form and JS- is found
2012 plants similar, and mouse challenge viral dosage shows that resJS- Δs BAC is identical with JS-2012 plants of virulence, and this display is from infectious gram
The grand middle viral resJS- Δs BAC saved out has and parent plant identical biological characteristics.
4.1 one step growth curves
PRV JS-2012, resJS-BAC, resJS- Δs BAC is inoculated with respectively with 1MOI and covers with Vero cell monolayer
In T25, be incubated 1h after, washed one time with DMEM, in each blake bottle plus 5ml 2%FBS DMEM inoculation after respectively with inoculation after
Culture supernatant 500ul is taken respectively at 4,8,12,16,20,24,28,32,36,40h, and adds DMEMs of the 500ul containing 2%FBS.
The virus of different time points is diluted to 10 with 1: 10-1To 10-9Dilution factor, and be inoculated into and be grown on 96 porocyte culture plates
In Vero cell monolayer, each dilution factor connects 8 holes.After inoculating cell culture 4d, cytopathy of the observation per hole, according to
Reed-Muench methods calculate virus TCID50, utilize the viral one step growth curve of GraphPad Software on Drawing.Viral growth curves
Such as Figure 11, three strain virus have similar growth kinetics characteristic, but Revive virus resJS-BAC, resJS- Δ BAC highest
Titre is more slightly lower than parent's strain JS-2012.
4.2 plaque assays
Revive virus resJS-BAC, resJS- Δ BAC and parent poison PRV JS-2012 are used into DMEM culture mediums respectively
After dilution, Vero cells are inoculated with, after being incubated 1 hour, virus liquid are discarded, PBS is washed twice, 3ml is added per hole and contains 1% low melting point
The covering culture medium of agarose and 2%FBS.After room temperature solidification, culture 3d is inverted in 37 DEG C, 5%CO2, with 5% crystal violet
Dyeing, as a result such as Figure 12.In fig. 12, Revive virus resJS- Δs BAC and parent poison PRV JS-2012 after BAC carrier are deleted
Plaque form is consistent, and size is close, and the resJS-BAC of the sequence containing BAC is less than normal than JS-2012.
The pathogenic experiment of 4.3 mouse
Respectively with 104TCID50/ only with 105TCID50/ only PRV JS-2012 and resJS- Δ BAC subcutaneous abdomens inoculation 7
SPF grades of Kunming female mices of week old, 5 groups, are compareed totally containing one group by inoculum of DMEM by every group 10.Observation mouse is dead daily
Situation is died, mouse survival curve is drawn.As a result such as Figure 13,104TCID50It is inoculated with (13A), resJS- Δs BAC survival rate and dead
Die the time and PRV JS-2012 are completely the same；105TCID50It is inoculated with (13B), resJS- Δs BAC and PRV JS-2012 inoculation groups
Completely dead, the death time concentrates on 4d and 5d after inoculation, but resJS- Δs BAC is slightly higher in the 4d death rates.This shows,
Revive virus is deleted after BAC sequences, maintains the strong malicious features of parent plant JS-2012.
Embodiment 5 builds gE/gI deleted virus using galk positive and reverse screening system operatios pJS2012-BAC
The present embodiment utilizes galk positive and reverse screening systems, and gE/gI bases are lacked on PRV infection clones pBAC-JS2012
Cause, constructs gE/gI deleted virus resJS2012- Δ gE/gI, so as to establish JS-2012 infection clones pBAC-
JS2012 operating method.Specific implementation process is as follows：
5.1 positive screenings
With reference to electric method for transformation in embodiment 3, pBAC-JS2012 plasmid electricity is rotated into SW102 bacterial strains, contained
PBAC-JS2012 bacterial strains SW102-BAC.
Using plasmid pGalk as template, galk expression cassettes, PCR reactions are expanded using primer galkup/galkdown (table 1)
System：94 DEG C of 4min, 94 DEG C of 1Ss, 60 DEG C of 30s, 72 DEG C of 1min, carry out 30 circulations altogether；72℃ 10min.PCR primer
Electrophoresis result such as Figure 14 (1：DNA Marker DL2000,2：PCR primer), amplification obtains 1300bp or so purpose band, glue
Reclaim the band.
The electric transformed competence colibacillus of SW102-BAC bacterial strains is prepared, according to electric method for transformation in embodiment 3, galk bands are turned
Enter SW102-BAC.Transformed bacteria is applied into M63 flat boards, and (15g Agar are dissolved in the sterilizing of 800ml deionized waters mesohigh, then add
200ml5xM63,1ml 1M MgSO4,10ml 20% galactolipin, 5ml 0.2mg/ml biotins, 4.5ml 10mg/ml L- are bright
After propylhomoserin, 500ul chloramphenicol (25mg/ml), sterilized petri dishes, obtain M63 flat boards) just screened.After 32 DEG C of culture 3d, choose
Take bacterium colony to cultivate 16h in the LB liquid containing chloramphenicol (25 μ g/ml), directly using bacterium solution be template, PgBDF/PgBDR with
LgalkDF/LgalkDR (table 1) enters performing PCR screening gB and galk positive colonies, PCR amplifications such as Figure 15 (1 for primer：DNA
Marker DL2000,2-7：PgBDF/PgBD qualification results, 8-13：LgalkDF/LgalkDR qualification results), 6 detected
Individual clone, can amplify gB genetic fragments, but wherein only have 3 clones to detect galk genes, and size is consistent with expection.
Because LgalkDF is located at galk recombination sites upstream in JS-2012 genomes, LgalkDR is located in galk genes, LgalkDF/
LgalkDR amplifies fragment, then shows in galk genetic recombination such as viral genome.Therefore, three amplify fragment clone
For positive colony, SW102-BAC-galk+ is named.Confirm galk sequence as shown in SEQ ID NO.23 after sequencing.
5.2 counter-selections
Using pBAC-JS2012 as template, expanded using primer LgEgIF/LgEgIR and RgEgIF/RgEgIR left and right homologous
Arm, left homology arm fragment such as Figure 16 (1：DNA Marker DL2000,2：Left homology arm), right homology arm fragment such as Figure 17 (1：
DNA Marker DL2000,2：Right homology arm), a length of 500bp of two homology arms or so.The left homology arm of glue reclaim, right homology arm and
Eco RV digestion pBluescriptSK carriers, using vitro recombination kit Gibson Assembly Master Mix by it is left,
Right restructuring arm is connected with carrier, obtains negative screening transfer vector pSKDEI.With the negative screening transfer of XhoI and BamHI double digestions identification
Carrier, such as Figure 18 (1：DNA Marker DL5000,2：pSKDEI-1、3：PSKDEI-2), can be by pSKDEI digestions into 1000bp
With 3000bp or so two bands, it is consistent with sequence analysis profiling results.
Using pSKDEI as template, with LgEgIF/RgEgIR (table 1) for primer, PCR amplifications obtain DNA fragmentation DgE/gI.Ginseng
According to the method for embodiment 3, DgE/gI fragment electricity is transferred in SW102-BAC-galk+, transformed bacteria is applied into M63 bears screening flat board
(15g Agar are dissolved in the sterilizing of 800ml deionized waters mesohigh, then add 200ml 5xM63,1ml 1M MgSO4,10ml 20%
The glycerine of DOG, 10ml 20%, 5ml 0.2mg/ml biotins, 4.5ml 10mg/ml L-Leus, 500ul chloramphenicol (25mg/
Ml after), sterilized petri dishes, obtain M63 and bear screening flat board).After 32 DEG C of culture 3d, picking colony is in containing chloramphenicol (25 μ g/ml)
32 DEG C of LB liquid culture 16h, enter performing PCR for primer using LgEgIF/RgEgIR and identify.PCR primer electrophoresis result such as Figure 19
(M1：DNA Marker DL5000,1-21：Detect sample, c：PBAC-JS2012 is compared, M2：DNA Marker
DL2000), 15 bacterium colony cultures amplify 1000bp band, are positive bacterium colony, and the pBAC- of the non-missings of gE/gI
JS2012 expands bp bands more than 2000.Positive colony is referred to as pBACJS- Δs gE/gI (SEQ ID NO.25).
5.3resJS- Δ gE/gI virus rescues
PBACJS- Δ gE/gI are extracted from positive colony bacterium solution using NucleoBond Xtra Midi kits, to turn
2ug pBACJS- Δ gE/gI transfected Vero cells are obtained virus resBACJS- Δs gE/gI by transfection reagent FuGENE 6.With
It may occur in which that green fluorescence expresses (Figure 20) in cell after resBACJS- Δ gE/gI vero cells infections, infection 20h.With reference to implementation
The method of example 1.3, using the transfection reagents of FuGENE 6 by 2ug pcDNA3.1-cre transfected Vero cells, then with resBACJS-
Δ gE/gI infection cells.Treat that 60% lesion occurs in cell, harvest supernatant, carry out Plaque-purified.Selected by three-wheel without green
The plaque of fluorescent protein expression, obtains virus and is referred to as resJS- Δs gE/gI.
5.4resJS- Δs gE/gI is identified
ResJS- Δ gE/gI genomes are extracted, are identified with LgEgIF/RgEgIR (table 1) PCR, sequencing result such as SEQID
Shown in NO.22.Compared with JS-2012 genomes, one section of gI gene coding region the 571st is contained in resJS- Δ gE/gI genomes
Position nucleotides to 1211 nucleotides in gE gene coding regions missing (Figure 21).
Vero cells in 6 orifice plates are infected with resJS- Δs gE/gI, while using JS-2012 infection as positive control, DMEM
Infect for negative control, using this laboratory gE monoclonal antibodies as primary antibody, sheep anti-mouse igg is secondary antibody, existed with IFA detections
The expression of gE albumen in resJS- Δ gE/gI infection cells.Such as Figure 22 (A：PRV JS-2012, B：ResJS2012- Δ gE/gI,
C：negative control.), only it is presented green fluorescence in street strain JS-2012 infection cells, and resJS- Δs gE/gI
It is identical with the negative control cell that DMEM is inoculated with, fluorescence is had no, this shows that resJS- Δs gE/gI does not express gE albumen.
5.5resJS- Δ gE/gI biological property analysis
With reference to the method for embodiment 4.1 and 4.2, compare resJS- Δs gE/gI and parent plant JS-2012 one step growth curve
And plaque form.One step growth curve (Figure 23) result shows that resJS- Δ gE/gI growth rates are compared with JS-2012, slightly
Decline.Plaque assay (Figure 24) shows that resJS- Δ gE/gI plaques are less than normal than JS-2012.This shows deleting for gE/gI genes
Remove, the propagation and iuntercellular that can influence virus spread.
The invention is not limited in foregoing embodiment.The present invention, which is expanded to, any in this manual to be disclosed
New feature or any new combination, and disclose any new method or process the step of or any new combination.
Claims (10)
1. a kind of construction method of Pseudorabies virus infection clones, it is characterised in that the described method comprises the following steps：
1) by methods of homologous recombination, in Pseudorabies virus gG gene ORF terminator codons downstream, insertion both wings contain loxp's
EGFP expression cassettes, obtain recombinant virus rJS2012-gG/EGFP；Using Cre enzymes and loxp sites, EGFP expression cassettes are deleted, are obtained
Obtain the recombinant virus rJS2012-gG/loxp that loxp is inserted in gG gene ORF terminator codons downstream；
2) Cre-loxp is utilized, the pBeloBAC11 carriers of EGFP expression cassettes will be inserted between BamHI-HindIII restriction enzyme sites
It is recombined into rJS2012-gG/loxp, obtains in recombinant virus rJS2012-BAC, the recombinant virus, pBeloBAC11 carrier sequences
Row are located at gG downstream of gene；
3) by the genomic DNA electricity conversion DH10B bacteriums during rJS2012-BAC infection cells, Orbivirus gene contains
PBeloBAC11, can breed in bacterium, by screening, obtain the plasmid pBAC-JS2012 of viral genomic clone.
2. a kind of construction method of Pseudorabies virus infection clones as claimed in claim 1, wherein described pseudoabies
Poison is selected from JS-2012 plants of PRV variants.
3. the Pseudorabies virus infection clones that method according to claim 1 or 2 is built.
4. Pseudorabies virus infection clones as claimed in claim 3, it is characterised in that described Pseudorabies virus is selected from
JS-2012 plants of PRV variants.
5. the Pseudorabies virus infection clones described in claim 3 or 4 are preparing the reagent or medicine of detection Pseudorabies virus
In purposes.
6. the Pseudorabies virus infection clones described in claim 3 or 4 are preparing prevention or treatment Pseudorabies virus diease occurrence thing
Purposes in product.
7. a kind of construction method for the Pseudorabies virus infection clones for preparing gE/gI missings, methods described comprises the following steps：
1) the plasmid pBAC-JS2012 of viral genomic clone, is obtained as claimed in claim 1；
2), using galk positive and reverse screening systems, gE/gI genes are lacked on PRV infection clones pBAC-JS2012, gE/ is obtained
The Pseudorabies virus infection clones pBACJS- Δs gE/gI of gI missings.
8. a kind of construction method of Pseudorabies virus infection clones for preparing gE/gI missings as claimed in claim 7, wherein
Described Pseudorabies virus is selected from JS-2012 plants of PRV variants.
9. the Pseudorabies virus infection clones for the gE/gI missings that method according to claim 8 is built.
10. a kind of the Pseudorabies virus infection clones and natural infection strain of the gE/gI missings distinguished described in claim 8
Detection method, it is characterised in that comprise the following steps：Enter performing PCR using LgEgIF/RgEgIR for primer to identify, gE/gI missings
Pseudorabies virus infection clones amplify 1000bp band, be positive bacterium colony, and the natural sense of the non-missings of gE/gI is contaminated
Strain expands bp bands more than 2000.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710118726.9A CN106939320B (en) | 2017-03-01 | 2017-03-01 | Infectious clone plasmid of pseudorabies virus JS-2012 strain, construction method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710118726.9A CN106939320B (en) | 2017-03-01 | 2017-03-01 | Infectious clone plasmid of pseudorabies virus JS-2012 strain, construction method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106939320A true CN106939320A (en) | 2017-07-11 |
| CN106939320B CN106939320B (en) | 2020-09-18 |
Family
ID=59468680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710118726.9A Active CN106939320B (en) | 2017-03-01 | 2017-03-01 | Infectious clone plasmid of pseudorabies virus JS-2012 strain, construction method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106939320B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111875678A (en) * | 2020-07-07 | 2020-11-03 | 华南农业大学 | Recombinant pseudorabies virus for expressing GP3/GP5/M gene of porcine reproductive and respiratory syndrome virus, construction method and application |
| CN113684190A (en) * | 2021-04-29 | 2021-11-23 | 山东农业大学 | Circovirus type 3 double-copy full-length gene infectious clone plasmid and construction method and application thereof |
| CN114717204A (en) * | 2022-03-08 | 2022-07-08 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | Replication-defective pseudorabies virus and construction method and application thereof |
| CN114807223A (en) * | 2022-03-17 | 2022-07-29 | 新疆方牧生物科技有限公司 | Construction method of porcine epidemic diarrhea virus infectious clone |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1940063A (en) * | 2005-09-29 | 2007-04-04 | 华中农业大学 | Pseudo-rabies gE/gI-gene loss poison strain, killed vaccine containing it and use |
| US20100291142A1 (en) * | 2007-10-18 | 2010-11-18 | Roger Maes | Bacterial Artificial Chromosome Containing Feline Herpes Virus Type 1 Genome and Uses Thereof |
| CN104152416A (en) * | 2014-01-03 | 2014-11-19 | 中国农业科学院上海兽医研究所 | Pseudorabies virus gene-deleted attenuated strain as well as preparation method and application thereof |
| CN106282132A (en) * | 2015-05-11 | 2017-01-04 | 中国农业科学院上海兽医研究所 | The low virulent strain of Pseudorabies virus variant and application thereof |
-
2017
- 2017-03-01 CN CN201710118726.9A patent/CN106939320B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1940063A (en) * | 2005-09-29 | 2007-04-04 | 华中农业大学 | Pseudo-rabies gE/gI-gene loss poison strain, killed vaccine containing it and use |
| US20100291142A1 (en) * | 2007-10-18 | 2010-11-18 | Roger Maes | Bacterial Artificial Chromosome Containing Feline Herpes Virus Type 1 Genome and Uses Thereof |
| CN104152416A (en) * | 2014-01-03 | 2014-11-19 | 中国农业科学院上海兽医研究所 | Pseudorabies virus gene-deleted attenuated strain as well as preparation method and application thereof |
| CN106282132A (en) * | 2015-05-11 | 2017-01-04 | 中国农业科学院上海兽医研究所 | The low virulent strain of Pseudorabies virus variant and application thereof |
Non-Patent Citations (8)
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111875678A (en) * | 2020-07-07 | 2020-11-03 | 华南农业大学 | Recombinant pseudorabies virus for expressing GP3/GP5/M gene of porcine reproductive and respiratory syndrome virus, construction method and application |
| CN113684190A (en) * | 2021-04-29 | 2021-11-23 | 山东农业大学 | Circovirus type 3 double-copy full-length gene infectious clone plasmid and construction method and application thereof |
| CN113684190B (en) * | 2021-04-29 | 2023-05-05 | 山东农业大学 | Infectious clone plasmid of circular virus 3 type double-copy full-length gene, construction method and application thereof |
| CN114717204A (en) * | 2022-03-08 | 2022-07-08 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | Replication-defective pseudorabies virus and construction method and application thereof |
| CN114717204B (en) * | 2022-03-08 | 2023-12-26 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | Replication-defective pseudorabies virus, construction method and application thereof |
| CN114807223A (en) * | 2022-03-17 | 2022-07-29 | 新疆方牧生物科技有限公司 | Construction method of porcine epidemic diarrhea virus infectious clone |
| CN114807223B (en) * | 2022-03-17 | 2024-05-31 | 新疆方牧生物科技有限公司 | Construction method of porcine epidemic diarrhea virus infectious clone |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106939320B (en) | 2020-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110079541B (en) | Method for constructing coronavirus infectious clone and application thereof | |
| CN109439634B (en) | Pseudorabies virus gene engineering attenuated vaccine strain and application thereof | |
| CN104894075A (en) | Method for preparing vaccine by editing pseudorabies virus genomes based on CRISPR/Cas9 and Cre/lox systems and application of method | |
| CN108103099B (en) | Anti-blue ear disease Marc-145 cell line and preparation method and application thereof | |
| CN107815441A (en) | A kind of II type Pseudorabies virus attenuated strain and its preparation method and application | |
| CN106939320A (en) | A kind of 2012 plants of infective cloned plasmids of Pseudorabies virus JS, construction method and application | |
| CN111849979B (en) | sgRNA for targeted knockout of RPSA gene and construction method of RPSA gene knockout cell line | |
| CN104152416B (en) | Pseudorabies virus gene delection low virulent strain and its preparation method and application | |
| US11285206B2 (en) | Heat-resistant recombinant Newcastle Disease Virus vaccine strain capable of expressing truncated Fiber 2 protein of Fowl Adenovirus serotype 4, preparation method and application thereof | |
| CN103981153A (en) | Construction of double fluorescence labeled deletion viruses of pseudorabies virus | |
| CN104946678B (en) | Marek's disease virus infectivity recombinant clone system and its construction method and application | |
| CN107384874A (en) | Pseudorabies virus epidemic strain gI/gE gene deletion mutants and structure and application | |
| CN100503816C (en) | Recombinant gene engineered strain of aujeszkys disease-porcine reproductive and respirator syndrome virus, and its uses | |
| CN107227311A (en) | Recombination porcine parvovirus like-particles and its preparation method and application | |
| CN101979598B (en) | Method for constructing HSV-1 BAC system carrying luciferase report genes | |
| CN106929485A (en) | Pseudorabies virus genetic engineering gB recombinates attenuated vaccine strain and application | |
| CN108434447B (en) | Toxoplasma toxoplasma attenuated live vaccine deleted OMPDC and LDH1 genes | |
| CN111773383B (en) | O-type foot-and-mouth disease subunit vaccine and preparation method and application thereof | |
| CN111334528B (en) | Mink enteritis parvovirus whole genome infectious clone and construction method and application thereof | |
| CN107296956A (en) | A kind of genetic recombination live vector vaccine | |
| CN115386556B (en) | Gene engineering vaccine for serially expressing gene recombination pseudorabies virus of African swine fever virus P30 and P54 and application thereof | |
| CN114107304B (en) | Recombinant coccidium vector for expressing alpha toxin protein and fluorescent tag protein and detection method thereof | |
| CN105385666B (en) | The building of 5 gene-deleted strain of pseudorabies virus double fluorescence labeling | |
| CN109666655B (en) | Fusarium graminearum single-stranded circular DNA virus FgGMTV1/HB58 and application thereof | |
| CN110013547B (en) | Rough brucella of recombinant peste des petits ruminants virus H gene and vaccine production method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |